Antibiotic LM 427
Antibiotic LM 427 Brand names, Antibiotic LM 427 Analogs
Antibiotic LM 427 Brand Names Mixture
- No information avaliable
Antibiotic LM 427 Chemical_Formula
C46H62N4O11
Antibiotic LM 427 RX_link
http://www.rxlist.com/cgi/generic2/rifabutin.htm
Antibiotic LM 427 fda sheet
Antibiotic LM 427 msds (material safety sheet)
Antibiotic LM 427 Synthesis Reference
No information avaliable
Antibiotic LM 427 Molecular Weight
847.005 g/mol
Antibiotic LM 427 Melting Point
No information avaliable
Antibiotic LM 427 H2O Solubility
Minimally soluble (0.19 mg/mL)
Antibiotic LM 427 State
Solid
Antibiotic LM 427 LogP
4.218
Antibiotic LM 427 Dosage Forms
Capsule
Antibiotic LM 427 Indication
For the prevention of disseminated Mycobacterium avium complex (MAC) disease in patients with advanced HIV infection.
Antibiotic LM 427 Pharmacology
Rifabutin is an antibiotic that inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme. It is bactericidal and has a very broad spectrum of activity against most gram-positive and gram-negative organisms (including Pseudomonas aeruginosa) and specifically Mycobacterium tuberculosis. Because of rapid emergence of resistant bacteria, use is restricted to treatment of mycobacterial infections and a few other indications. Rifabutin is well absorbed when taken orally and is distributed widely in body tissues and fluids, including the CSF. It is metabolized in the liver and eliminated in bile and, to a much lesser extent, in urine, but dose adjustments are unnecessary with renal insufficiency.
Antibiotic LM 427 Absorption
Rifabutin is readily absorbed from the gastrointestinal tract, with an absolute bioavailability averaging 20%.
Antibiotic LM 427 side effects and Toxicity
LD50 = 4.8 g/kg (mouse, male)
Antibiotic LM 427 Patient Information
Patients should be advised of the signs and symptoms of both MAC and tuberculosis, and should be instructed to consult their physicians if they develop new complaints consistent with either of these diseases. In addition, since MYCOBUTIN may rarely be associated with myositis and uveitis, patients should be advised to notify their physicians if they develop signs or symptoms suggesting either of these disorders.
Urine, feces, saliva, sputum, perspiration, tears, and skin may be colored brown-orange with rifabutin and some of its metabolites. Soft contact lenses may be permanently stained. Patients to be treated with MYCOBUTIN should be made aware of these possibilities.
Antibiotic LM 427 Organisms Affected
Enteric bacteria and other eubacteria
